Scott Solomon, MD
Cardiovascular Disease · Boston, MANPI 1528025996
Payments from drug & device makers
Across 362 payments — averaging $44,698 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5.7M
- AstraZeneca$3.7M
- Astrazeneca UK Limited$1.3M
- Ionis Pharmaceuticals, Inc.$1.2M
- Sanofi Pasteur Inc.$866K
- Amgen$714K
- plus $2.7M from 24 others
Across 9 payments — averaging $966.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$5K
- Bayer$2K
- Novartis$2K
- Amgen$151
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $5,714,271 |
| AstraZeneca(2 entities) | 55 | $3,732,087 |
| Astrazeneca UK Limited | 56 | $1,295,034 |
| Ionis Pharmaceuticals, Inc. | 8 | $1,196,344 |
| Sanofi Pasteur Inc. | 16 | $865,662 |
| Amgen | 6 | $713,509 |
| Applied Therapeutics, Inc. | 7 | $473,794 |
| Eli Lilly | 2 | $468,146 |
| GSK | 32 | $411,981 |
| Alnylam Pharmaceuticals Inc. | 10 | $305,539 |
| Bayer | 23 | $295,174 |
| Novartis Pharma AG | 60 | $270,627 |
| Novo Nordisk AS | 9 | $189,102 |
| ZOLL Respicardia, Inc. | 3 | $82,569 |
| Sumitomo Pharma America, Inc. | 2 | $65,139 |
| Astrazeneca AB | 11 | $36,343 |
| E.r. Squibb & Sons, L.L.C. | 13 | $25,275 |
| Boston Scientific | 5 | $11,706 |
| American Regent | 2 | $10,836 |
| Roche Diagnostics International Ltd | 3 | $6,384 |
| Roche Diagnostics Corporation | 8 | $4,301 |
| Actelion Pharmaceuticals, Ltd | 1 | $3,535 |
| Boehringer Ingelheim International GmbH | 1 | $1,300 |
| Sarepta Therapeutics, Inc. | 1 | $1,080 |
| Daiichi Sankyo Inc. | 1 | $577 |
| Sandoz | 1 | $125 |
| Modernatx, Inc. | 1 | $46 |
| Agepha Pharma FZ LLC | 1 | $16 |
| Seagen Inc. | 1 | $15 |
| Strongbridge US Inc. | 1 | $13 |
How this compares
$16,180,531 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Boston
- Marc SabatineBoston$31.2M
- Stephen WiviottBoston$29.2M
- David MorrowBoston$19M
- Paul RidkerBoston$16.2M
- Mohit JainBoston$13M
- Calum MacraeBoston$11.4M
- Benjamin SciricaBoston$11.3M
- Robert GiuglianoBoston$10.5M
- Erin BohulaBoston$10M
- Michelle OdonoghueBoston$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.